ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Ticker SymbolPROK
Company nameProKidney Corp
IPO dateJun 30, 2021
CEODr. Bruce Culleton, M.D.
Number of employees204
Security typeOrdinary Share
Fiscal year-endJun 30
Address2000 Frontis Plaza Blvd.
CityWINSTON-SALEM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27103
Phone13369997028
Websitehttps://prokidney.com/
Ticker SymbolPROK
IPO dateJun 30, 2021
CEODr. Bruce Culleton, M.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data